Porustobart - Harbour BioMed
Alternative Names: HBM-4003; HCAb-4003-2Latest Information Update: 28 Jul 2024
At a glance
- Originator Harbour BioMed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver cancer; Neuroendocrine tumours; Renal cell carcinoma; Solid tumours
- Phase I/II Malignant melanoma
- Clinical Phase Unknown Colorectal cancer
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (IV)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in China (IV)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, Late-stage disease, Metastatic disease) in China (IV)